Utebzi approved as first oral carbapenem for cUTIs in the US
GSK and Spero Therapeutics have secured FDA approval for Utebzi (tebipenem pivoxil), an oral carbapenem antibiotic for the treatment of complicated urinary tract infections (cUTIs), including pyelonephritis, in adult patients with limited or no alternative oral treatment options. The approval, announced on 17 June 2026, marks the first time a carbapenem antibiotic has been made available in an oral formulation in the United States.
Carbapenems are considered a last-resort class for severe or drug-resistant bacterial infections. Until now, their use has been confined to intravenous administration, requiring hospital admission and carrying the associated costs and clinical risks of prolonged in-patient stays. The ability to deliver carbapenem-class therapy orally creates a meaningful pathway to outpatient treatment for a patient group that has historically been difficult to manage outside a hospital setting.
Clinical evidence and trial data
The approval rests on results from the PIVOT-PO Phase III trial, a global, randomised, double-blind, non-inferiority study comparing oral tebipenem pivoxil (600 mg every six hours) with intravenous imipenem-cilastatin (500 mg every six hours) over seven to ten days in hospitalised adults with cUTIs. The primary endpoint was a composite of clinical cure and microbiological eradication at a test-of-cure visit approximately 17 days from first dose. Tebipenem pivoxil achieved an overall success rate of 58.5% (261 of 446 participants) against 60.2% (291 of 483) for imipenem-cilastatin, with an adjusted treatment difference of -1.3% (95% CI: -7.5%, 4.8%), comfortably within the pre-specified non-inferiority margin of -10%. The trial enrolled 1,690 patients in total.
The safety profile was described as broadly comparable to imipenem-cilastatin and other carbapenems. The most common adverse events, reported in at least 3% of patients, were diarrhoea and headache, both characterised as mild to moderate in severity. GSK said commercial supply is anticipated to reach US patients before the end of 2026.
Tony Wood, Chief Scientific Officer at GSK, said: "The approval of Utebzi provides the first and only oral carbapenem antibiotic for appropriate adults with complicated UTIs, a solution that could help reduce reliance on hospital-based intravenous care and support efforts to address resistant infections."
Market context and antimicrobial resistance landscape
The clinical and commercial backdrop for Utebzi is substantial. More than three million cUTI cases are managed annually in the United States, with treatment failure affecting roughly a third of patients. Healthcare costs attributable to cUTIs exceed six billion dollars per year, driven in large part by multidrug-resistant pathogens and the hospital resources required to deliver intravenous therapy.
Antimicrobial resistance continues to narrow the effective antibiotic pipeline. Regulatory agencies on both sides of the Atlantic have introduced incentive frameworks to encourage development in this area, including the US QIDP and Fast Track designations that tebipenem pivoxil received, and the UK's subscription-style reimbursement model for novel antibiotics. BARDA, the US government's biomedical preparedness agency, co-funded part of the development programme under two federal contracts, reflecting the strategic priority attached to new carbapenem-class options.
The competitive landscape for cUTI treatment includes other novel agents targeting resistant gram-negative pathogens, such as cefiderocol and imipenem-cilastatin-relebactam, both of which require intravenous delivery. An oral carbapenem occupies a distinct niche: it targets a step-down or outpatient population that existing agents cannot readily serve. Whether prescribers and payers will adopt Utebzi at scale will depend on pricing, formulary access, and real-world evidence of de-escalation outcomes, all of which remain to be established at launch.